Together, these studies established the conceptual framework that PD-1/PD-L1 interaction suppresses anti-tumor immunity, leading to the emergence of a new therapeutic paradigm: immune checkpoint blockade (Figure 1). This evidence concerns the gene PDCD1 and neoplasm.